CP-201 is an alkylphospholipid (APL), which has exiting and promising potential as a drug candidate

CP-201 is poised to enter phase 1 in oncology with evidence of utility in multiple indications with high unmet medical need


Potential to be a first in class, non-toxic, disease modifying agent for oncology

  • Efficacy in patient derived xenograft (PDX) models
  • Evidence of efficacy in glioblastoma and non-small cell lung cancer when tested in man as a racemic mixture
  • Evidence of radiosensitization potential in prostate cancer


Potential to be a safe and effective therapy for the treatment of multiple sclerosis

  • Preclinical scientific rationale via inhibition of T cell proliferation
  • Effective in both relapsing and chronic Experimental Autoimmune Encephalomyelitis (EAE) models


CP-201 is clinical-development ready

  • Encouraged to pursue development by BfArM (German Federal Institute for Drugs and Medical Devices)
  • API and drug product available
  • Phase 1 clinical sites in Australia ready to initiate phase 1